There are no Focus articles on RBGPY.
5 Investment Opportunities In The Home Care SectorDavid Hunkar • Jan. 17, 2012
There are no Transcripts on RBGPY.
There are no News articles on RBGPY.
Mon, Jul. 28, 4:48 AM
- Reckitt Benckiser (OTCPK:RBGLY) states that it will pursue a demerger of its pharmaceutical division, allowing it to put a greater focus on its core consumer health and hygiene business.
- The spinoff will occur in the next 12 months - becoming a separate U.K.-listed company.
- The announcement follows the Reckitt Benckiser's 7% drop in second-quarter revenue which fell to £2.3B from £2.5B Y/Y.
Mon, Jul. 21, 8:56 AM
- German private equity firm Aurelius has agreed to buy Reckitt Benckiser's (OTCPK:RBGLY) Scholl shoe business. The company is expecting the brand to expand internationally and maintain growth.
- Aurelius will acquire the international rights to the business, except for North and South America, which will go to Bayer (OTCPK:BAYRY) as part of its $14B purchase of Merck (NYSE:MRK).
- The deal is expected to close in the third quarter of 2014.
Sun, Apr. 27, 1:23 AM
- Merck (MRK) could agree a deal to sell its consumer healthcare operations this week for almost $14B, Reuters reports, with Germany's Bayer (BAYRY) and U.K.-based Reckitt Benckiser (RBGLY) the frontrunners to buy the unit.
- Other healthcare consumer giants have also also shown interest in the business, including Procter & Gamble (PG), Novartis (NVS) and Sanofi (SNY).
- Merck is looking to sell the operations as it only holds around 1% of the market.
- A deal would be the latest in a wave of blockbuster transactions to have swept the healthcare sector recently, such as Pfizer's $100B+ reported offer to acquire AstroZeneca, Valeant and Bill Ackman's $47B play for Allergan, Zimmer's agreement to purchase Biomet for $13.35B, and a series of deals involving Novartis, GlaxoSmithKline and Eli Lilly.
Wed, Apr. 16, 8:33 AM
- Reckitt Benckiser (RBGLY) could spin off its declining pharmaceuticals operations, saying that the idea is "emerging as a strong option." However, selling the business or even keeping it are still possible.
- The division's net sales dropped 15% in Q1 to £170M.
- Total net revenues declined 6% to £2.37B.
- Shares are +0.3% in London. (PR)
Tue, Mar. 25, 7:26 AM
- Sanofi (SNY) has joined the auction for Merck's (MRK) over-the-counter health-products business, Bloomberg reports.
- Final offers could value the unit at $10-12B and are due in next week.
- Reckitt Benckiser (RBGLY) is the frontrunner, having become the most aggressive bidder.
- "OTC assets are highly desirable for market incumbents as almost no additional infrastructure is required," says Barclays. Merck's unit would be a "good fit" geographically for Sanofi, as 70% of its revenue comes from the U.S.
- Other interested parties include Bayer (BAYRY).
Mon, Mar. 10, 9:05 AM
- Johnson & Johnson (JNJ) has agreed to sell the global rights to its K-Y brand of intimate lubricants to Reckitt Benckiser (RBGLY).
- While the price of the deal wasn't provided, Reckitt did say that K-Y had 2013 sales of over $100M, the majority of which was generated in the U.S. Canada and Brazil.
- K-Y adds to Reckitt's Durex brand.
- The transaction doesn't include staff or fixed assets. (PR)
Thu, Feb. 20, 4:33 AM
- Novartis (NVS) and Bayer (BAYRY) are among the suitors that are exploring an acquisition of Merck's (MRK) consumer-healthcare business, Reuters reports, adding that the unit could be worth $10-12B.
- Reckitt Benckiser (RBGPF) and Procter & Gamble (PG) are also among the companies to have held talks with Merck about a deal. However, GSK (GSK) is not interested.
- Novartis and Merck have considered swapping the latter's consumer-healthcare operations for Novartis' animal-health and human vaccines businesses, although such a deal is looking unlikely.
Aug. 20, 2013, 3:01 PM
- Mallinckrodt (MNK +0.5%) says it's agreed to distribute Amneal Pharmaceuticals' Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets, a generic version of Reckitt Benckiser's (RBGPY.PK) Suboxone, to addition treatment centers for a period of three years, with an option to extend.
- Related stocks: BDSI
Feb. 12, 2013, 8:15 AMBristol-Myers Squibb (BMY) licenses the rights to sell several of its top-selling medicines in Latin America to Reckitt Benckiser (RBGPY.PK) for $482M. Under the deal, the British company will be able to sell the medicines in countries such as Brazil and Mexico, and it has an option to acquire the brands outright after three years. (PR) | Comment!
May. 9, 2012, 12:15 PM
Apr. 14, 2011, 7:36 AM
There are no StockTalks on this stock yet.
RBGPY vs. ETF Alternatives
Other News & PR